DSG Helps Human Genome Achieve Phase III Success
8.17.09
Human Genome Sciences (HGS; Rockville, MD) credits EDC technology from DSG (Malvern, PA) for helping the company meet the primary endpoint in two Phase III trials of its Lupus drug BENLYSTA.
The study, BLISS-52, utilized DSG's eCaseLink EDC software to capture data and support data management in their Herculean task of monitoring the nearly 400 electronic case report forms per subject.
“This was our first experience with EDC, and DSG really helped lead the way," said Pierre Verroye, Executive Director of Clinical Data Management and Clinical Programming, HGS, in a company press release. "Sites and CRAs gave us a lot of positive feedback about the eCaseLink system.”
If BENLYSTA is approved, it will be the first drug approved in decades for people living with systemic lupus.
Behind the Buzz: Why Clinical Research Leaders Flock to SCOPE Summit
February 7th 2025In this episode, we meet with Micah Lieberman, Executive Conference Director for SCOPE Summit (Summit for Clinical Ops Executives) at Cambridge Innovation Institute. We will dive deep into the critical role of collaboration within the clinical research ecosystem. How do we bring together diverse stakeholders—sponsors, CROs, clinical trial tech innovators, suppliers, patients, sites, advocacy organizations, investors, and non-profits—to share best practices in trial design, program planning, innovation, and clinical operations? We’ll explore why it’s vital for thought leaders to step beyond their own organizations and learn from others, exchanging ideas that drive advancements in clinical research. Additionally, we’ll discuss the pivotal role of scientific conferences like SCOPE Summit in fostering these essential connections and collaborations, helping shape the future of clinical trials. Join us as we uncover how collective wisdom and cross-industry partnerships are transforming the landscape of clinical research.
Reaching Diverse Patient Populations With Personalized Treatment Methods
January 20th 2025Daejin Abidoye, head of solid tumors, oncology development, AbbVie, discusses a number of topics around diversity in clinical research including industry’s greatest challenges in reaching diverse patient populations, personalized treatment methods, recruitment strategies, and more.
